Citations

Clear

237 citation(s) found for "Veronica, N".

Impact of a collaborative care-based symptom intervention model on chemotherapy adherence in patients with breast cancer.
Ruddy, Kathryn J. , Grzegorczyk, Veronica , Hassett, Michael J. , Greenmyer, Jacob R. , Pachman, Deirdre R. , Storandt, Michael H. , Kroenke, Kurt , Mitchell, Sandra A , Smith, Ashley Wilder , Cheville, Andrea

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 1543-1543

10.1200/jco.2025.43.16_suppl.1543 Get It

1543 Background: Treatment toxicity may limit the ability of cancer patients to receive all recommended cycles of therapy. Four to six cycles of docetaxel plus cyclophosphamide (TC) is a common adjuvant chemotherapy regimen for early-stage breast cancer. We assessed the impact of routine collection of patient-reported outcomes (PROs), coupled with a collaborative care model-based symptom management intervention, on the number of cycles of TC received by patients with breast cancer. Methods: The Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) trial was a cluster-randomized, pragmatic clinical trial, conducted between March 2019 and January 2023 at Mayo Clinic Rochester and within the Mayo Clinic Health System in Minnesota and Wisconsin. Patients regularly reported the severity of 6 SPPADE symptoms (Sleep deficit, Pain, Physical function impairment, Anxiety, Depression, and Energy deficit/fatigue) on 11-point numerical rating scales. Each symptom score was interpreted as none to mild (0-3), moderate (4-6), or severe (7-10). The E2C2 intervention included symptom management education modules, clinician decision support aids, and the option to discuss severe symptoms with a nurse, physical therapist, or social worker. Patients with breast cancer who received at least one cycle of TC were included in this analysis. We compared the number of cycles of docetaxel and cyclophosphamide completed by patients in the control condition versus those in the intervention condition. Results: We identified 198 patients with breast cancer who received TC during the control condition and 128 who received TC during the intervention condition. Median age was 61.3 years in the control group and 60.3 years in the intervention group, and 94% and 95% were white, respectively. Those receiving treatment during the control condition, on average, completed 3.53 cycles of docetaxel, while those receiving TC during the intervention condition completed 3.77 cycles ( p = 0.014). Seventy-eight percent in the control group completed at least 4 cycles of docetaxel, compared to 84% in the intervention group. Those receiving TC during the control condition completed an average of 3.71 cycles of cyclophosphamide, compared to 3.78 cycles in the intervention condition (p = 0.231). Eighty-four percent of patients in the control group and 86% in the intervention group completed at least 4 cycles of cyclophosphamide. Conclusions: Routine PRO surveillance, coupled with guideline-based collaborative care interventions, was associated with completion of a greater number of cycles of docetaxel. These findings suggest that routine symptom surveillance and management may enhance the docetaxel tolerance profile and improve treatment adherence in patients with early-stage breast cancer, allowing for delivery of an optimized treatment course.
The Breakthrough discoveries for thriving with bipolar disorder (BD2) Integrated Network Longitudinal Cohort Protocol
Baxi, Emily G. , Shanahan, Meg, Pham, Dániel , Beck, Veronica C., Barcomb, Kelsey M., Nestler, Eric J. , Altimus, Cara M. , Shanahan, Megan, Beck, Veronica C. , Nestler, Eric J., Frye, Mark A. , Burdick, Katherine E.

Mayo Clinic

No container title available | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6566177/v1 Get It

Abstract Bipolar Disorder (BD) is a highly complex and heterogeneous disorder. As such, accurate diagnosis is often delayed, and effective treatment options are limited. The Integrated Network, a program of Breakthrough Discoveries for thriving with Bipolar Disorder (BD 2 ), was designed as a platform for longitudinal deep phenotyping of a diverse group of people with bipolar disorder to define disease trajectories and to gain insight into the biological drivers of the illness. Biosamples, including whole blood, serum, plasma, and peripheral blood mononuclear cells (PBMCs) will be collected longitudinally and will also be made available. The Integrated Network is designed to be the largest and most comprehensive prospective longitudinal study conducted in bipolar disorder, allowing for the development of precision-based treatment strategies that optimize quality of life for people living with bipolar disorder.
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
Wang, Michael , Song, Yuqin, Jurczak, Wojciech, Kahl, Brad S. , Chu, Michael P., Kryachok, Iryna, Fogliatto, Laura, Cheah, Chan Y. , Morawska, Marta , Li, Yufu, Patti, Caterina , Forsyth, Cecily , Lesley, Robin, Ramadan, Safaa, Rule, Simon, Dreyling, Martin , investigators, for the ECHO, Cazap, Nicolás, Foncuberta, María Cecilia, Garate, Gonzalo, Gustavo, Jarchum, Pavlovsky, Miguel Arturo , Riveros, Dardo, Baker, Ross, Butler, Jason, Cannell, Paul , Cheah, Chan, Forsyth, Cecily, Giri, Pratyush, Johnston, Amanda, Lee, Denise , Lee, Hui‐Peng, Mapp, Sally, Roncolato, Fernando , Thant, Aung , Walker, Patricia, Doo, Nicole Wong, Demuynck, Hilde, Offner, Fritz , Hende, Vanessa Van, Vergote, Vibeke, Wu, Ka Lung , Chiattone, Carlos, Azevedo, Sergio de, Fogliatto, Laura, Fonseca, Ana, Hamerschlak, Nelson, Lazaretti, Nicolas, Rocha, Vanderson, Salvino, Marco, Santucci, Rodrigo, Schaan, Mariza, Scheliga, Adriana, Vieira, Garles Miller, Berinstein, Neil, Boutin, Mélina , Chu, Michael, Keating, Mary‐Margaret, Schattner, Ariah, Restrepo, Diego Villa, Cen, Xinan, Du, Xin, Feng, Ru, Gao, Sujun, Huang, Haiwen, Ji, Jie, Jin, Jie, Ke, Xiaoyan, Li, Dengju, Li, Fei, Li, Jianyong, Li, Junmin, Li, Yan, Li, Yufu, Li, Zhenyu, Lin, Li'e, Liu, Tingbo, Lv, Fangfang , Shuang, Yuerong, Sun, Lan, Sun, Xiuhua, Wang, Zhao, Wu, Huijing, Xi, Yaming, Xia, Ruixiang, Xue, Hongwei, Yang, Haiyan, Yi, Shuhua, Zhang, Cheng, Zhang, Huilai, Zhang, Mingzhi, Zhang, Qingyuan, Zhao, Xielan, Zhou, Hui, Hajek, Roman, Jindra, Pavel , Mayer, Jiri, Novak, Jan, Abraham, Julie, Bijou, Fontanet, Bouabdallah, Kamal , Cymbalista, Florence, Guilbert, Sophie, Laribi, Kamel, Rodon, Philippe, Decker, Thomas, Dreger, Peter, Dreyling, Martin, Hess, Georg, Lenz, Georg, Stilgenbauer, Stephan, Tummes, Dirk, Anargyrou, Konstantinos , Dimopoulos, Meletios-Athanassios, Kapsali, Eleni, Kyriakou, Despoina, Panayiotidis, Panayiotis, Pappa, Vasiliki , Stavroyianni, Niki, Cheng, Hoi Ching, Kwong, Yok-Lam, Lee, Harold, Ng, Ting Ying, Wong, Raymond, Borbényi, Zita , Illés, Árpád, Lázár, Zsolt, Nagy, Ágnes , Nagy, Zsolt, Schneider, Tamas, Avivi, Irit, Gurion, Ronit, Horowitz, Netanel, Ronson, Aaron, Arcaini, Luca, Boccomini, Carola, Ghia, Paolo, Luminari, Stefano, Plenteda, Caterina, Santoro, Armando, Zilioli, Vittorio Ruggero, Zinzani, Pier Luigi, Choi, Ilseung , Ennishi, Daisuke , Ichikawa, Satoshi, Ishikawa, Takayuki, Izutsu, Koji, Kato, Koji, Maruyama, Dai, Nagai, Hirokazu, Ota, Shuichi, Saito, Toko, Sakai, Rika, Suzuki, Ritsuro, Uoshima, Nobuhiko , Yano, Takahiro, Yoshida, Isao, Eom, Ki-Seong, Kim, Jin Seok, Kim, Seok Jin, Lee, Jung-Hee, Mun, Yeung Chul, Yoon, Sung Soo , Arreguin, Elsa Veronica Avila, Andrade, Adriana Dominguez, Almaguer, David Gómez, Vera, Maria Silvia Rivas, Anaya, Luis Solís, Berkahn, Leanne, Pemberton, Lucy, Simpson, David, Beltrán, Brady, Quintana, Shirely, Revilla, Jose Carlos, Vargas, Ernesto, Grosicki, Sebastian , Hałka, Janusz , Jedrzejczak, Wieslaw, Knopińska-Posłuszny, Wanda, Krzanowski, Jacek, Lech-Maranda, Ewa, Robak, Tadeusz, Rzepecki, Piotr , Wróbel, Tomasz, Borsaru, Gabriela, Ciuleanu, Tudor Eliade, Danaı̈la, Catalin, Lazaroiu, Mihaela, Alexeeva, Julia, Chistyakov, Valeriy, Manikhas, Georgy, Mikhailova, Natalia, Proydakov, Andrey, Volodicheva, Elena , Voloshin, Sergey, Bastos, Mariana, Cordoba, Raul, Codina, José , Gonzalez, Eva Maria, Marin, Ana, Panizo, Carlos, Rodriguez, Guillermo, Salar, Antonio, Sancho, Juan-Manuel, Velo, Jose A, Chiu, Chang-Fang, Hsiao, Liang-Tsai, Kuo, Ching-Yuan, Lin, Tung-Liang, Lysa, Tamila, Maslyak, Zvenyslava, Nogaieva, Larysa, Polenkov, Sergey, Usenko, Ganna, Agajanian, Richie, Anz, Bertrand, Chaudhry, Arvind, Chiu, Alden , Cultrera, Jennifer, D’Olimpio, James, Dunleavy, Kieron, Fanning, Suzanne, Flinn, Ian, Gabrail, Nashat, Gallinson, David, Goldenberg, Alec, Graf, Solomon, Grover, N., Hess, Brian, Hoffman, Marc, Isufi, Iris, Kahl, Brad, Kambhampati, Suman , Kirkel, Dean, Diaz, Guillermo Lazo, Levy, Moshe, Liu, Delong, Mead, Monica , Paludo, Jonas, Patel, Anjan, Peles, Shachar, Persky, Daniel, Portell, Craig, Rosenthal, Allison, Sano, Dahlia , Smith, Sonali , Smith, Stephen, Spurgeon, Stephen, Tache, Jason, Tsai, Michaela, Veltri, Lauren, Wang, Michael, Yimer, Habte, Bach, Quoc Khanh, Đỗ, Huyền Nga, Luu, Hung Vu, Khoa, Trọng, Phạm, Như Hiệp, Panizo, Carlos , Kriachok, Iryna , Kahl, Brad S , Paludo, Jonas , Cheah, Chan Yoon , Morawska, Marta , Sancho, Juan-Manuel , Forsyth, Cecily , Dreyling, Martin , Belada, David , Song, Yuqin , Paludo, Jonas , Fogliatto, Laura , Zhang, Jingyang , Lesley, Robin, Ramadan, Safaa Mahmoud , Garate, Gonzalo, Riveros, Dardo Alberto, Cannell, Paul , Cochrane, Tara , Giri, Pratyush, Mapp, Sally , Doo, Nicole Wong , Demuynck, H, Hende, Vanessa Van, Vergote, Vibeke K. J. , CHIATTONE, CARLOS SÉRGIO , Farias, João Samuel de Holanda , Fonseca, Ana Rita Da , Rocha, Vanderson , Oliveira, José Salvador Rodrigues de , Scheinberg, Phillip , Scheliga, Adriana , Vieira, Garles Miller Matias , Berinstein, Neil Lorne , Shuang, Yuerong , Hájek, Roman , Mayer, Jiřı́ , Bijou, Fontanet , Cymbalista, Florence, Delwail, Vincent , Genet, Philippe , Dreger, Peter , Heß, Georg , Lenz, Georg , Stilgenbauer, Stephan , Kapsali, Eleni , Katodritou, Eirini , Kyriakou, Despoina S, Panayiotidis, Panayiotis G. , Symeonidis, Argiris , Schneider, Tamas J., Avivi, Irit, Gurion, Ronit , Horowitz, Netanel A. , Arcaini, Luca , Boccomini, Carola , Luminari, Stefano , Santoro, Armando, Zilioli, Vittorio Ruggero , Zinzani, Pier Luigi , Fukushima, Kentaro , Izutsu, Koji , Maruyama, Dai , Tatetsu, Hiro , Kim, Sang‐A , Oh, Sung Yong , Arreguin, Elsa Ávila, Gómez‐Almaguer, David , Issa, Samar , Revilla, Jose C., Vargas, Ernesto, Lech-Maranda, Ewa, Robak, Tadeusz , Borsaru, Gabriela, Ciuleanu, Tudor–Eliade , Danaila, Catalin-Doru , Alexeeva, Julia, Briones, Javier , Salar, Antonio , Yuste, Victor Jimenez, Chen, Chien‐Yuan , Kuo, Ching‐Yuan, Anz, Bertrand, Cultrera, Jennifer L. , D’Olimpio, James, Dunleavy, Kieron , Gabrail, Nashat , Gallinson, David, Goldenberg, Alec S., Goy, Andre Henri , Graf, Solomon A. , Hess, Brian, Kirkel, Dean, Portell, Craig A. , Rosenthal, Allison , Stevens, Don, Veltri, Lauren Westfall , Yimer, Habte, Tran, Thanh Tung

Mayo Clinic

Journal of Clinical Oncology | May 1, 2025 | Volume: 43 | Issue: 20 | Pages: 2276-2284

10.1200/jco-25-00690 | PMID 40311141 Get It

PURPOSE The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely because of toxicity. Acalabrutinib was shown to be efficacious and less toxic than ibrutinib in a head-to-head trial in chronic lymphocytic leukemia and therefore might lead to better outcomes in MCL. METHODS Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine (90 mg/m 2 once daily; days 1 and 2) and rituximab (375 mg/m 2 as a single dose; day 1) followed by rituximab maintenance in responding patients for 2 years. Crossover to acalabrutinib at disease progression was permitted. The primary end point was PFS per the independent review committee; overall response rate and OS were secondary end points. RESULTS In total, 598 patients were randomly assigned, with 299 in each arm. At a median follow-up of 49.8 months using the reverse Kaplan-Meier method, the median PFS was 66.4 months in the acalabrutinib arm and 49.6 months in the placebo arm (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.94]; P = .0160). Benefit was seen across all subgroups, including those with high-risk features. Overall response/complete response rates were 91.0%/66.6% and 88.0%/53.5% in the acalabrutinib and placebo arms, respectively. OS was not significantly different (HR, 0.86 [95% CI, 0.65 to 1.13]; P = .27). Grade 3 or greater adverse events were reported in 88.9% and 88.2% in the acalabrutinib and placebo arms, respectively. CONCLUSION The combination of acalabrutinib with bendamustine-rituximab significantly improved PFS. Clinical benefit of acalabrutinib with bendamustine-rituximab was achieved with manageable toxicity.
Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment
Sperduto, Paul W. , Marqueen, Kathryn E. , Chang, Enoch , Li, Jing , Davies, Michael A. , Ebner, Daniel K. , Breen, William G. , Lamba, Nayan , Shih, Helen A. , Mahal, Amandeep R. , Rahman, Rifaquat , Ankrah, Nii, Boggs, Drexell H. , Lewis, Calvin D. , Hyer, Daniel E. , Johri, Fasila, Soliman, Hany , Masucci, Laura , Chiang, Veronica , Phuong, Christina , Dajani, Salah, Wan, Zihan, Niedzwiecki, Donna , Vaios, Eugene , Pasetsky, Jared , Wang, Tony J. C. , Kotecha, Rupesh , Ross, Richard B. , Rusthoven, Chad G. , Nakano, Toshimichi , Tawbi, Hussein A. , Edwards, Donna , Kim, Michelle M , Rahman, Rifaquat , Boggs, Drexell H , Lewis, Calvin , Hyer, Daniel , Buatti, John M , Aneja, Sanjay , Chiang, Veronica , Phuong, Christina , Braunstein, Steve , Sachdev, Sean , Niedzwiecki, Donna , Vaios, Eugene , Pasetsky, Jared , Wang, Tony J C , Kotecha, Rupesh , Ross, Richard B , Rusthoven, Chad G , Nakano, Toshimichi , Tawbi, Hussein , Mehta, Minesh P , Shih, Helen A , Kim, Michelle M. , Buatti, John M. , Roberge, David , Braunstein, Steve , Kirkpatrick, John P. , Kütük, Tuğçe , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | April 17, 2025 | Volume: 43 | Issue: 16 | Pages: 1910-1919

10.1200/jco-24-01351 | PMID 40245362 Get It

PURPOSE Survival for patients with melanoma has recently improved. The propensity of melanoma to metastasize to the brain remains a common and serious feature of this disease. The purposes of this study were to evaluate prognostic factors for patients with newly diagnosed melanoma brain metastases (MBMs) in a large cohort treated with modern multimodal therapies, compare those results with those in prior eras, and update the Melanoma Graded Prognostic Assessment (GPA). METHODS Univariable and multivariable (MVA) analyses of prognostic factors and treatments associated with survival were performed on 1,796 patients with newly diagnosed MBM treated between January 01, 2015, and December 31, 2021, using a multi-institutional retrospective database. Multiple imputation was used to address missingness of potential predictors. Significant variables in combined MVA were used to update the Melanoma GPA. Comparisons were made with legacy cohorts. RESULTS Median survivals for cohorts A (1985-2007, n = 481), B (2006-2015, n = 823), and C (2015-2021, n = 1,796) were 6.7, 9.8, and 16.6 months and median follow-up times were 40.1, 43.6, and 48.8 months, respectively. In combined MVA, significant prognostic factors for survival were higher Karnofsky Performance Status, fewer MBMs, absence of extracranial metastases, lower serum lactate dehydrogenase, and no immunotherapy before MBM. These factors were incorporated into the updated Melanoma GPA. The combined median and 3-year survivals for patients with GPA 0-1, 1.5-2, and 2.5-4.0 were 5.4, 13.2, and 43.2 months and 12.4%, 28.8%, and 51.6%, respectively. CONCLUSION Prognostic factors have changed and survival has improved for patients with MBM but varies widely by GPA. The updated Melanoma GPA calculator (BrainMetGPA), available free online, can be used to estimate survival, individualize treatment, stratify clinical trials, guide surveillance, and augment clinical trial eligibility. Multidisciplinary treatment is essential. Trials are needed to elucidate the optimal sequencing of various therapeutic modalities.
Clinical neurocardiology: defining the value of neuroscience‐based cardiovascular therapeutics – 2024 update
Aksu, Tolga , Arora, Rishi , Chen, Peng‐Sheng , Fudim, Marat , Herring, Neil , Po, Sunny S. , Stavrakis, Stavros , Somers, Virend K. , Tan, Alex Y. , Valderrábano, Miguel , Shivkumar, Kalyanam , Shivkumar, Kalyanam , Ajijola, Olujimi A. , Biaggioni, Italo , Ferrari, Gaetano Maria De , Dusi, Veronica , Goldberger, Jeffrey J , Green, Alexander L. , Khalsa, Sahib S. , Kumar, Rajesh , Lakatta, Edward G. , Mehra, Reena , Meyer, Christian , Somers, Virend K.

Mayo Clinic

The Journal of Physiology | March 12, 2025 | Volume: 603 | Issue: 7 | Pages: 1781-1839

10.1113/jp284741 | PMID 40056025 Get It

AbstractThe intricate role of the autonomic nervous system (ANS) in regulating cardiac physiology has long been recognized. Aberrant function of the ANS is central to the pathophysiology of cardiovascular diseases. It stands to reason, therefore, that neuroscience‐based cardiovascular therapeutics hold great promise in the treatment of cardiovascular diseases in humans. A decade after the inaugural edition, this White Paper reviews the current state of understanding of human cardiac neuroanatomy, neurophysiology and pathophysiology in specific disease conditions, autonomic testing, risk stratification, and neuromodulatory strategies to mitigate the progression of cardiovascular diseases. image
Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease
Goyal, Gaurav , Bossert, Dana, Sigler, Allison , Rotemberg, Veronica , Francis, Jasmine H. , Rampal, Raajit K. , Diamond, Eli L. , Reiner, Anne S , Francis, Jasmine H , Diamond, Eli L , Goyal, Guarav , Reiner, Anne S. , Lacouture, Mario E. , Go, Ronald S.

Mayo Clinic

Blood | March 7, 2025 | Volume: 145 | Issue: 18 | Pages: 2100-2103

10.1182/blood.2024028032 | PMID 40053897 Get It

Abstract Among 64 patients with Erdheim-Chester disease treated with a BRAF inhibitor (median follow-up 4 years), we found high response rates (85%) but frequent discontinuations (61%), primarily because of adverse events. Additionally, patients experienced poor health-related quality of life and high symptom burden.
Update on the Assessment of GFR in Patients with Cancer
Silva, Verônica T. Costa e , Xiong, Fei , Mantz, Lea , Sise, Meghan E. , Herrmann, Sandra M. , Kitchlu, Abhijat , Herrmann, Sandra M , Kitchlu, Abhijat , Xiong, Fei

Mayo Clinic

Kidney360 | February 24, 2025 | Volume: 6 | Issue: 5 | Pages: 861-870

10.34067/kid.0000000736 | PMID 39992722 Get It

Accurate assessment of GFR is key in patients with cancer to guide drug eligibility, adjust dosing of systemic therapy, and minimize the risks of undertreatment and systemic toxicity. Several aspects of GFR evaluation in patients with cancer have been unclear, such as the choice of the GFR estimating equation and the overall lack of data on the reliability of new filtration markers, such as cystatin C. This uncertainty has led to concerns that inaccurate GFR estimation may have a large effect on clinical practice and research. Recent data have brought important developments to the field. The new and timely Kidney Disease Improving Global Outcomes 2024 Clinical Practice Guideline for the Evaluation and Management of CKD raised important considerations and provided guidance on key aspects of GFR evaluation in patients with cancer. The guidelines cover valid estimating equations, incorporation of cystatin C in GFR estimation, drawbacks of using race in GFR estimation, and acknowledge that non-GFR determinants of filtration markers may be prominent in patients with cancer, reducing the accuracy of GFR estimating equations, prompting greater utilization of GFR measurement. The aim of this review is to summarize advances in GFR evaluation in patients with cancer considering the new Kidney Disease Improving Global Outcomes guidelines and other recent data.
1161: THE NEW GLOBAL DEFINITION OF ARDS RECENTLY INTRODUCED A SUBGROUP KNOWN AS NONINTUBATED ARDS
Olaizola, Gustavo , Saleem, Faiz , Raavi, Lekhya , Jonna, Sadhana , Siassi, Zara, Jena, Anek , Pareek, Aayushi , Hanson, Abby , Shapiro, Anna B, Bhattacharyya, Ankur, Chaudhary, Sanjay, Monzón, Verónica , Patel, Neal M. , Sanghavi, Devang , Isha, Shahin , Bisso, Indalecio Carboni , Jenkins, Anna , Milian, Ricardo Diaz , Guru, Pramod , Huespe, Iván

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001103308.61607.f1 Get It

Prolactin-induced sensitization of trigeminal nociceptors promotes migraine co-morbidity in endometriosis
Lee, Grace J. , Hode, Veronica, Georgieva, Teodora , Rau, Jill C. , Schwedt, Todd J. , Neugebauer, Volker , Porreca, Frank , Navratilova, Edita , Schwedt, Todd J , Porreca, Frank , Navratilova, Edita , Dodick, David W.

Mayo Clinic

Cephalalgia | January 15, 2025 | Volume: 45 | Issue: 1 | Pages: No page available

10.1177/03331024241313378 | PMID 39814523 Get It

Background Women with endometriosis are more likely to have migraine. The mechanisms underlying this co-morbidity are unknown. Prolactin, a neurohormone secreted and released into circulation from the anterior pituitary, can sensitize sensory neurons from female, but not male, rodents, monkeys and human donors. Methods We used a syngeneic model of endometriosis to determine whether elevated prolactin levels can sensitize trigeminal ganglion neurons and increase vulnerability to migraine pain. Results Mice with endometriotic lesions showed increased serum prolactin levels and developed persistent abdominal, but not cephalic, allodynia. However, inhalation of a transient receptor potential ankyrin 1 agonist, umbellulone, a known environmental trigger of headache in some patients, elicited cephalic allodynia in mice with endometriosis but not sham controls, suggesting that endometriosis can promote sensitization of trigeminal neurons and migraine attacks. Endometriosis dysregulated the expression of prolactin receptor isoforms in trigeminal neurons and increased their excitability measured by in vitro patch clamp electrophysiology. Inhibition of pituitary prolactin following a 2-week treatment with a dopamine receptor agonist, cabergoline, prevented cephalic allodynia elicited by activation of trigeminal afferents with umbellulone. Cabergoline treatment also normalized the expression of prolactin receptor isoforms in trigeminal ganglia and the hyperexcitability of trigeminal neurons. Conclusions These data demonstrate that circulating prolactin in endometriosis promotes vulnerability to migraine through sensitization of trigeminal afferents. Clinically available dopamine receptor agonists or novel monoclonal antibodies targeting prolactin signaling may be effective for migraine prevention in women with endometriosis.
Local control and patient survival after stereotactic radiosurgery for esophageal cancer brain metastases: an international multicenter analysis
Singh, Raj , Bowden, Greg , Perlow, Haley K. , Elhamdani, Shahed, Shepard, Matthew J., Liang, Yun , Reda, Wael A. , Tawadros, Sameh R. , Eldin, Reem Emad, Elazzazi, Ahmed Hesham, Warnick, Ronald E. , Gozal, Yair M., Daly, Megan, McShane, Brendan, Addis-Jackson, Marcel, Karthikeyan, Gokul, Franzini, Andrea , Hess, Judith, Templeton, Kelsey, Wei, Zhishuo , Pikis, Stylianos , Peker, Selçuk , Samancı, Yavuz , Chiang, Veronica , Lee, Cheng-chia, Niranjan, Ajay , Lunsford, L. Dade , Sheehan, Jason P. , Perlow, Haley K , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mathieu, David , Palmer, Joshua D. , Elhamdani, Shahed, Nabeel, Ahmed M. , Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Eldin, Reem M. Emad, Karthikeyan, Gokul, Smith, Sian K. , Picozzi, Piero , Kaisman‐Elbaz, Tehila , Yang, Huai‐Che , Mantziaris, Georgios , Šimonová, Gabriela , Liščák, Roman , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | December 6, 2024 | Volume: 142 | Issue: 5 | Pages: 1357-1365

10.3171/2024.7.jns24920 | PMID 39642356 Get It

OBJECTIVE This study aimed to evaluate local control (LC) of tumors, patient overall survival (OS), and the safety of stereotactic radiosurgery (SRS) for esophageal cancer brain metastases (EBMs). METHODS This retrospective cohort study used data from 15 International Radiosurgery Research Foundation facilities encompassing 67 patients with 185 EBMs managed using SRS between January 2000 and May 2022. The median patient age was 63 years, with a male predominance (92.5%). Most patients (64.2%) had a single brain metastasis, while 7.5% had more than 5 metastases. The median tumor volume was 0.9 cm 3 , and the median margin dose delivered to the tumor was 20 Gy. RESULTS The median OS post-SRS was 15.2 months, with 1- and 2-year OS rates of 65.7% and 32.3%, respectively. A significant inverse correlation was found between the number of EBMs and OS in the univariable analysis. LC rates at 1 and 2 years were 89% and 76%, respectively. Adverse radiation effects (AREs) were observed in 17.9% of patients, with 13.4% being mild and transient and 4.5% severely symptomatic (Common Terminology Criteria for Adverse Events grade 3). New intracranial disease developed in 58.2% of patients, with 1- and 2-year rates of 58% and 73%, respectively. CONCLUSIONS SRS for EBMs demonstrated high survival rates and effective tumor control, with a low incidence of severe AREs. These findings highlight the potential role of SRS in the multidisciplinary multimodality management paradigm of EBM.